J&J partner Genscript faces suspicious allegations

Oct 01, 2018

A research report has alleged major safety violations by Genscript’s subsidiary, Nanjing Legend Biotech, that has partnered with Johnson & Johnson.

The report, from obscure research company, Flaming Research, alleged that Nanjing Legend Biotechnology (Legend operates in USA, Hong Kong, mainland China and Ireland) bypassed standard safety procedures while testing an experimental gene therapy on Chinese cancer patients. It accused parent company GenScript of cherry picking results disclosed to investors, according to WSJ.

China-based Genscript was pushed into the spotlight after Legend presented impressive results for its BCMA-targeting CAR-T at the 2017 American Society of Clinical Oncology (ASCO) meeting.

According to the Pharma Letter, Genscript is now consulting lawyers after what they say is a “misleading” CAR-T report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments